# Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)

Source: https://onco.cc/trials/nct07496229/  
OnCo record `nct07496229` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Golidocitinib in peripheral T-cell lymphomas, run by Dizal Pharmaceuticals, now recruiting.

## Summary

Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3) is a phase 1/2 interventional study registered as NCT07496229 by Dizal Pharmaceuticals, with 165 participants planned, started 2026-04-15 and due to reach its primary completion in 2029-09. Interventions recorded: GW5282 combined with Golidocitinib and Conventional CHOP regimen.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07496229
- Phase: 1/2
- Setting: A Phase I/II Clinical Study to Evaluate the Efficacy and Safety of GW5282 in Combination With Golidocitinib in the Treatment of T-Cell Lymphoma
- Sponsor: Dizal Pharmaceuticals
- Enrolled: 165

## Sources

- ClinicalTrials.gov NCT07496229: https://clinicaltrials.gov/study/NCT07496229

## Connected records

- cancers: [Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)](https://onco.cc/cancers/peripheral-t-cell-lymphoma/)
- drugs: [Golidocitinib](https://onco.cc/drugs/golidocitinib/)
- companies: [Dizal Pharmaceutical](https://onco.cc/companies/dizal/)

---
JSON: https://onco.cc/api/v1/entities/nct07496229.json